Humanized anti-HER2 IgG1 monoclonal antibody that inhibits HER2/ERBB2 signaling and mediates antibody-dependent cellular cytotoxicity (ADCC).
Humanized IgG1 monoclonal antibody against HER2/ERBB2 that binds HER2 on tumor cells, inhibits HER2 signaling and receptor dimerization to suppress proliferation, and engages Fc receptors to mediate antibody-dependent cellular cytotoxicity (ADCC), with possible complement-dependent cytotoxicity, in HER2-overexpressing cancers.
NO
INDIRECT
Trastuzumab binds HER2 on tumor cells and engages CD16a on NK cells via its Fc to trigger ADCC; CD16a+ cells act as effectors and are not killed.
HER2-targeted bispecific IgG1 monoclonal antibody that binds two non-overlapping HER2 epitopes (trastuzumab- and pertuzumab-like), blocking HER2 dimerization and signaling and inducing ADCC.
Bispecific IgG1 monoclonal antibody that binds two non-overlapping HER2 epitopes (trastuzumab- and pertuzumab-like), blocking HER2 heterodimerization and downstream signaling (e.g., PI3K/AKT/MAPK) and inducing antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
YES
DIRECT
KN026 binds HER2 on tumor cells and engages immune effector cells via its Fc (FcγR on NK cells/macrophages) to induce ADCC (and potentially CDC), leading to target-cell lysis; blockade of HER2 signaling can also promote apoptosis.
HER2-targeted bispecific IgG1 monoclonal antibody that binds two non-overlapping HER2 epitopes (trastuzumab- and pertuzumab-like), blocking HER2 dimerization and signaling and inducing ADCC.
Bispecific IgG1 monoclonal antibody that binds two non-overlapping HER2 epitopes (trastuzumab- and pertuzumab-like), blocking HER2 heterodimerization and downstream signaling (e.g., PI3K/AKT/MAPK) and inducing antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
YES
DIRECT
IgG1 antibody binds HER2 on tumor cells and engages Fcγ receptor–bearing immune effectors (e.g., NK cells, macrophages) to mediate ADCC/ADCP, killing HER2+ cells; also blocks HER2 signaling (cytostatic).
Anti-HER2 IgG1 monoclonal antibody that inhibits HER2 signaling and mediates antibody-dependent cellular cytotoxicity (ADCC).
Humanized IgG1 monoclonal antibody that binds the HER2 receptor, blocks receptor dimerization and downstream signaling, and elicits immune-mediated killing of HER2-overexpressing tumor cells via antibody-dependent cellular cytotoxicity (ADCC).
YES
DIRECT
Trastuzumab binds HER2 on target cells and its Fc engages Fcγ receptors on NK cells/other effectors to elicit ADCC (perforin–granzyme); some CDC may contribute.
Anti-HER2 IgG1 monoclonal antibody that blocks HER2 dimerization and mediates antibody-dependent cellular cytotoxicity (ADCC).
Humanized anti-HER2 IgG1 that binds the HER2 extracellular dimerization domain, blocks HER2 dimerization and downstream signaling (e.g., PI3K/AKT/MAPK), and engages Fc-gamma receptor–bearing effector cells to mediate ADCC, leading to tumor cell growth inhibition and death.
YES
DIRECT
Pertuzumab binds HER2, blocks HER2 dimerization/signaling (inducing apoptosis) and engages FcγR-bearing effector cells to mediate ADCC against HER2+ cells.